Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.
Tonneijck L, Smits MM, Muskiet MHA, Hoekstra T, Kramer MHH, Danser AHJ, Diamant M, Joles JA, van Raalte DH. Tonneijck L, et al. Among authors: van raalte dh. Diabetologia. 2016 Jul;59(7):1412-1421. doi: 10.1007/s00125-016-3938-z. Epub 2016 Apr 1. Diabetologia. 2016. PMID: 27038451 Free PMC article. Clinical Trial.
Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Tonneijck L, Smits MM, Muskiet MH, Hoekstra T, Kramer MH, Danser AH, Ter Wee PM, Diamant M, Joles JA, van Raalte DH. Tonneijck L, et al. Among authors: van raalte dh. Diabetes Care. 2016 Nov;39(11):2042-2050. doi: 10.2337/dc16-1371. Epub 2016 Sep 1. Diabetes Care. 2016. PMID: 27585605 Clinical Trial.
Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
Tonneijck L, Muskiet MHA, Smits MM, Hoekstra T, Kramer MHH, Danser AHJ, Diamant M, Joles JA, van Raalte DH. Tonneijck L, et al. Among authors: van raalte dh. Diabetes Obes Metab. 2017 Dec;19(12):1669-1680. doi: 10.1111/dom.12985. Epub 2017 Jul 25. Diabetes Obes Metab. 2017. PMID: 28449402 Clinical Trial.
SGLT2 inhibition: a new era in renoprotective medicine?
Muskiet MHA, Heerspink HJL, van Raalte DH. Muskiet MHA, et al. Among authors: van raalte dh. Lancet Diabetes Endocrinol. 2017 Aug;5(8):569-571. doi: 10.1016/S2213-8587(17)30222-X. Epub 2017 Jun 27. Lancet Diabetes Endocrinol. 2017. PMID: 28666776 No abstract available.
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
Muskiet MHA, Tonneijck L, Smits MM, van Baar MJB, Kramer MHH, Hoorn EJ, Joles JA, van Raalte DH. Muskiet MHA, et al. Among authors: van baar mjb, van raalte dh. Nat Rev Nephrol. 2017 Oct;13(10):605-628. doi: 10.1038/nrneph.2017.123. Epub 2017 Sep 4. Nat Rev Nephrol. 2017. PMID: 28869249 Review.
Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
Tonneijck L, Muskiet MHA, Smits MM, Bjornstad P, Kramer MHH, Diamant M, Hoorn EJ, Joles JA, van Raalte DH. Tonneijck L, et al. Among authors: van raalte dh. Diabetes Obes Metab. 2018 May;20(5):1235-1245. doi: 10.1111/dom.13223. Epub 2018 Feb 20. Diabetes Obes Metab. 2018. PMID: 29341461 Free PMC article. Clinical Trial.
214 results